Literature DB >> 18188029

Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985-2004.

Rune Erichsen1, Peter Jepsen, Jacob Jacobsen, Mette Nørgaard, Hendrik Vilstrup, Henrik T Sørensen.   

Abstract

OBJECTIVES: Changes, over the last 20 years, in the diagnostic procedures and treatment of primary liver cancer (PLC) and liver metastases of unknown origin (LMUO) may have affected the clinical course of both cancers. Few longitudinal studies examined this issue. In a population-based setting, we studied changes in the incidence and prognosis of PLC and LMUO over time.
METHODS: Between 1985 and 2004, we identified 2675 patients with PLC and LMUO in three Danish counties, with a population of 1.4 million. We computed the standardized incidence rate (SIR), ratio of PLC to LMUO diagnoses, median survival, and estimated mortality rate ratio adjusted for age, sex, and comorbidity.
RESULTS: The SIR of PLC increased from 3.2 in 1985 to 5.0 in 2003, and the SIR of LMUO increased from 3.7 to 6.4. No increase was noted in the PLC-to-LMUO ratio over time (P=0.1 for trend). From 1985 to 2004, the median survival of PLC patients increased from 1.6 to 2.9 months whereas that of LMUO patients decreased from 1.7 to 1.3 months. Adjusting for age, sex, and comorbidity did not affect the mortality rate ratio estimates.
CONCLUSIONS: The incidence of both PLC and LMUO increased over time, whereas the PLC-to-LMUO ratio remained unchanged. Median survival of PLC patients has increased whereas that of LMUO patients remained practically unchanged.

Entities:  

Mesh:

Year:  2008        PMID: 18188029     DOI: 10.1097/MEG.0b013e3282f17517

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

1.  Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study.

Authors:  Jiaping Li; Fujun Zhang; Jianyong Yang; Yingqiang Zhang; Yu Wang; Wenzhe Fan; Yonghui Huang; Wei Wang; Henry Ran; Shi Ke
Journal:  Target Oncol       Date:  2014-10-08       Impact factor: 4.493

2.  Unfavorable cancers of unknown primaries: presentation and prognostic factors. A population-based 8-year experience.

Authors:  Margareta Randén; Maria Helde-Frankling; Sara Runesdotter; Peter Gunvén
Journal:  Med Oncol       Date:  2013-09-18       Impact factor: 3.064

3.  Multiple target-specific molecular imaging agents detect liver cancer in a preclinical model.

Authors:  S Ke; F Zhang; W Wang; X Qiu; J Lin; A G Cameron; C Zou; X Gao; C Zou; V F Zhu; M Li
Journal:  Curr Mol Med       Date:  2012-09       Impact factor: 2.222

4.  Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo.

Authors:  Chris Zhiyi Zhang; Yinghua Pan; Yun Cao; Paul B S Lai; Lili Liu; George Gong Chen; Jingping Yun
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

5.  Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma.

Authors:  Chris Zhiyi Zhang; Lili Liu; Muyan Cai; Yinghua Pan; Jia Fu; Yun Cao; Jingping Yun
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

6.  Survival of patients with primary liver cancer in central and northern Denmark, 1998-2009.

Authors:  Jonathan Montomoli; Rune Erichsen; Mette Nørgaard; Morten Høyer; Jesper Bach Hansen; Jacob Bonde Jacobsen
Journal:  Clin Epidemiol       Date:  2011-07-21       Impact factor: 4.790

7.  Incidence and comparative prognosis of cancers with metastasis to noncommon sites: A population-based study.

Authors:  Basel Abdelazeem; Kirellos Said Abbas; Deepti Nagaraja Rao; Rabeet Tariq; Ahsan Wahab
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

8.  Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis.

Authors:  Rongzhen Luo; Meifang Zhang; Lili Liu; Shixun Lu; Chris Zhiyi Zhang; Jingping Yun
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

9.  Hsp60 exerts a tumor suppressor function by inducing cell differentiation and inhibiting invasion in hepatocellular carcinoma.

Authors:  Jing Zhang; Xingchun Zhou; Hulin Chang; Xiaojun Huang; Xu Guo; Xiaohong Du; Siyuan Tian; Lexiao Wang; Yinghua Lyv; Peng Yuan; Jinliang Xing
Journal:  Oncotarget       Date:  2016-10-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.